How MOGENRY's gene-agnostic mechanism differs from a mutation-specific gene therapy
The FDA just accepted for review a gene therapy for retinitis pigmentosa that doesn't care which gene caused it.
It works by giving surviving retinal cells a new way to sense light, not by fixing the mutation.
Nanoscope Therapeutics said on September 9 that the FDA has accepted and filed its Biologics License Application (BLA), the formal request to approve a biologic, for MOGENRY. It is an investigational optogenetic gene therapy, meaning it adds a light-sensing gene to eye cells, for retinitis pigmentosa (RP) patients with severe vision loss. Nanoscope says that, if approved, it would be the first treatment for RP with severe vision loss that works regardless of which gene is mutated.
MOGENRY, known chemically as sonpiretigene isteparvovec and also called MCO-010, does not correct the mutation causing a patient's RP. It targets surviving retinal cells instead, and does not require genetic testing to determine who qualifies. RP is an inherited eye disease in which the retina's light-sensing cells are lost.
What the FDA accepted
The FDA has accepted and filed the Biologics License Application for MOGENRY® (sonpiretigene isteparvovec, MCO-010), Nanoscope Therapeutics' investigational gene therapy for vision restoration. It is aimed at retinitis pigmentosa patients with severe vision loss.
Nanoscope CEO Sulagna Bhattacharya described the BLA acceptance as a milestone for the company.
If approved, MOGENRY would be the first gene-agnostic treatment for RP patients with severe vision loss.
Eyewire News reports that the FDA has set a PDUFA date in the first half of 2027. That is the FDA's target date for a decision, named after the Prescription Drug User Fee Act. Nanoscope's own release does not give the date.
The gene-agnostic framing is the whole story here: most gene therapies are built to fix one specific mutation, and MOGENRY isn't.
MOGENRY, at a glance
- Indication: retinitis pigmentosa with severe vision loss; gene-agnostic, so no genetic test is required to qualify.
- Clinical package: a Phase 1/2a trial (NCT04919473) plus the RESTORE trial (NCT04945772), which Nanoscope calls Phase 2b/3 and which met its primary and key secondary endpoints with visual acuity gains at weeks 52 and 76; Nanoscope's announcement did not give the size of the improvement.
- Decision timing: FDA target decision (PDUFA) date in the first half of 2027, per Eyewire News.
- Regulatory designations: FDA Fast Track and Orphan Drug (RP and Stargardt), plus Regenerative Medicine Advanced Therapy (RMAT) for Stargardt; EMA orphan, Sakigake and orphan in Japan, and orphan in Saudi Arabia.
- Pipeline: the same MCO-010 gene is in the Phase 2 STARLIGHT trial for Stargardt disease (NCT05417126), with a Phase 3 registrational Stargardt trial planned for 2026, a Phase 2 geographic atrophy program planned for 2026, and a Leber congenital amaurosis program ready to enter human trials.
Why "gene-agnostic" is the unusual part
Retinitis pigmentosa is not caused by a single mutation: different patients carry mutations in different genes. Most gene therapies for RP are built to correct one specific mutation, which is why they typically require genetic testing to confirm which therapy fits which patient.
MOGENRY skips that step. Instead of correcting the causative mutation, it targets surviving retinal bipolar cells directly, delivering a multi-characteristic opsin (MCO) gene that makes those cells light-sensitive on their own.
If you've solved a problem like this, Drug Development experts get matched to paid consulting work through GTC's Expert Network: join free.
How it's meant to be given: no surgical suite required
MOGENRY is designed as a one-time, in-office intravitreal injection: a shot into the eye, not an operation. It does not require invasive surgery or repeat dosing.
Designed as a one-time, in-office intravitreal injection: no surgery, no repeat dosing.
Nanoscope has designed it for administration within existing retina office workflows, rather than a surgical suite. Dr. Allen C. Ho (Professor of Ophthalmology at Thomas Jefferson University, Director of Retina Research at Wills Eye Hospital, and Nanoscope's Chief Medical Advisor) has pointed to this design choice.
He said that because MOGENRY needs neither genetic testing nor a surgical suite, it could enable broad adoption by community retina practices. He added that, if approved, it could bring treatment within reach of patients who do not have access to a major academic hospital. Those are the views of Nanoscope's adviser, not trial findings.
The data behind the BLA
A Phase 1/2a trial (NCT04919473) and the RESTORE trial (NCT04945772) support the BLA. Nanoscope describes RESTORE as a Phase 2b/3 randomized, double-masked, sham-controlled study. ClinicalTrials.gov lists it as Phase 2 with 27 participants enrolled.
RESTORE met its primary endpoint and key secondary endpoints, with improvements in visual acuity recorded at weeks 52 and 76. Nanoscope's announcement does not state the size of that improvement. The therapy was well tolerated, with no treatment-related serious adverse events.
RESTORE met its primary endpoint, with visual acuity gains recorded at weeks 52 and 76.
Most RESTORE participants continued into REMAIN, a long-term follow-up study also included in the BLA package. Dr. SriniVas Sadda chairs Nanoscope's Visionary Advisory Committee and is based at UCLA's David Geffen School of Medicine and the Doheny Eye Institute. He has said MOGENRY shows evidence of a sustained effect for years, which is what doctors need to see in a one-time treatment.
Where MOGENRY sits in Nanoscope's pipeline
Nanoscope develops disease-agnostic, vision-restoring optogenetic therapy for retinal degenerative diseases, and MOGENRY is its lead program. The same MCO-010 gene is also being tested in the Phase 2 STARLIGHT trial (NCT05417126) for Stargardt disease, a separate inherited retinal condition.
Nanoscope has said a Phase 3 registrational trial in Stargardt disease is planned to start in 2026. MCO-010 already carries FDA Fast Track and Orphan Drug designations for both RP and Stargardt, plus Regenerative Medicine Advanced Therapy (RMAT) designation for Stargardt. Designations like these signal FDA engagement, not a guaranteed approval.
It also holds EMA orphan designations, Sakigake and orphan designation in Japan, and orphan designation in Saudi Arabia for inherited retinal dystrophies. Nanoscope expects to start a Phase 2 geographic atrophy program in 2026, and lists a program in Leber congenital amaurosis (LCA) that is ready to file for human trials (IND-ready).
What this means for a CGT program
MOGENRY's core pitch to the field is a delivery-model claim, not just an efficacy claim. It is a one-time intravitreal injection given in an ordinary retina office, with no genetic-testing gate and no surgical suite required. That is a different commercial-access bar than an ocular gene therapy that depends on subretinal surgical delivery or genetic testing to confirm who is even eligible.
GTC analysis: for a program benchmarking site-of-care and manufacturing (CMC) or delivery-device planning against ocular gene therapy comparators, an intravitreal, gene-agnostic product resets what "commercial-access-friendly" looks like. A program that requires subretinal surgical delivery or genetic-testing-gated eligibility now has to justify that added infrastructure burden in its differentiation messaging, not assume it as the category default.
Frequently asked questions
What is MOGENRY?
MOGENRY (sonpiretigene isteparvovec, also called MCO-010) is Nanoscope Therapeutics' investigational optogenetic gene therapy for vision restoration in retinitis pigmentosa patients with severe vision loss.
The FDA has accepted and filed its Biologics License Application.
What does "gene-agnostic" mean, and why is it unusual for a gene therapy?
Most gene therapies correct the specific mutated gene causing a disease. MOGENRY instead delivers a multi-characteristic opsin (MCO) gene into surviving retinal bipolar cells, making them directly light-sensitive, regardless of which gene originally caused the patient's retinitis pigmentosa.
That means it does not require genetic testing to determine eligibility.
What data supports Nanoscope's BLA for MOGENRY?
The BLA is supported by a Phase 1/2a trial (NCT04919473) and the RESTORE trial (NCT04945772), which Nanoscope describes as a Phase 2b/3 randomized, double-masked, sham-controlled study.
RESTORE met its primary and key secondary endpoints, with improvements in visual acuity at weeks 52 and 76. Nanoscope's announcement did not give the size of that improvement. No treatment-related serious adverse events were observed.
If approved, how would MOGENRY be given?
MOGENRY is designed as a one-time, in-office intravitreal injection. It does not require invasive surgery, repeat dosing, or genetic testing, and is intended for administration within existing retina office workflows rather than a surgical suite.
Sources
- Nanoscope Therapeutics Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa with Severe Vision Loss, Nanoscope Therapeutics press release, September 9, 2026
- FDA Accepts Nanoscope's BLA for Optogenetic Gene Therapy Mogenry in Retinitis Pigmentosa, Eyewire News, September 9, 2026
- Optogenetic Gene Therapy: Nanoscope Announces FDA Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa, eyefox.com, September 11, 2026
- Dose-Escalation Study of Intravitreal vMCO-I in Advanced Retinitis Pigmentosa, Phase 1/2 (NCT04919473), ClinicalTrials.gov
- Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE], listed as Phase 2 (NCT04945772), ClinicalTrials.gov
- Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease (STARLIGHT), Phase 2 (NCT05417126), ClinicalTrials.gov
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.